SAN DIEGO, June 11, 2025 - Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced new and updated clinical data from its FT819 program for the treatment of moderate-to-severe systemic lupus erythematosus $(SLE)$. The data were presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain. The initial clinical profile of the FT819 off-the-shelf CAR T-cell program showed significant disease improvement in all five patients dosed, with the first patient reaching a 12-month follow-up and demonstrating durable drug-free remission. The company is expanding its clinical footprint in the U.S. and Europe and plans to discuss registrational strategies with the FDA for FT819 under its Regenerative Medicine Advanced Therapy (RMAT) designation. Fate Therapeutics has approximately 450 cryopreserved drug product bags of FT819 in inventory for patient treatment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。